malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication
暂无分享,去创建一个
Robert W. Sauerwein | Ashley J. Birkett | Timothy N. C. Wells | Fredros O. Okumu | Regina Rabinovich | David C. Kaslow | Quique Bassat | Q. Bassat | F. Okumu | L. Slutsker | J. Vekemans | D. Kaslow | R. Sauerwein | R. Rabinovich | T. Wells | A. Birkett | Johan Vekemans | Laurence Slutsker
[1] M. Tanner,et al. malERA: An updated research agenda for health systems and policy research in malaria elimination and eradication , 2017, PLoS medicine.
[2] B. F. Hall,et al. malERA: An updated research agenda for malaria elimination and eradication , 2017, PLoS medicine.
[3] Modelling,et al. malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication , 2017, PLoS medicine.
[4] malERA Refresh Consultative Panel. malERA: An updated research agenda for characterising the reservoir and measuring transmission in malaria elimination and eradication , 2017, PLoS medicine.
[5] K. Paaijmans,et al. malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication , 2017, PLoS medicine.
[6] D. Kwiatkowski,et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. , 2017, The Lancet. Infectious diseases.
[7] D. Fidock,et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study , 2017, The Lancet. Infectious diseases.
[8] J. Burrows,et al. New developments in anti-malarial target candidate and product profiles , 2017, Malaria Journal.
[9] Richard J. Maude,et al. Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria , 2017, PloS one.
[10] N. White. Why Do Some Primate Malarias Relapse? , 2016, Trends in Parasitology.
[11] Paige E. Waterman,et al. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. , 2016, The Journal of infectious diseases.
[12] M. Parker,et al. Development of drugs for severe malaria in children , 2016, International health.
[13] Division on Earth. Gene Drives on the Horizon: Advancing Science, Navigating Uncertainty, and Aligning Research with Public Values , 2016 .
[14] H. Chandel,et al. Prevalence of pfhrp2 and/or pfhrp3 Gene Deletion in Plasmodium falciparum Population in Eight Highly Endemic States in India , 2016, PloS one.
[15] S. Meshnick,et al. Estimation of Plasmodium falciparum Transmission Intensity in Lilongwe, Malawi, by Microscopy, Rapid Diagnostic Testing, and Nucleic Acid Detection. , 2016, The American journal of tropical medicine and hygiene.
[16] Division on Earth. COMMITTEE ON GENE DRIVE RESEARCH IN NON-HUMAN ORGANISMS: RECOMMENDATIONS FOR RESPONSIBLE CONDUCT , 2016 .
[17] Werayut Srituravanich,et al. The development of malaria diagnostic techniques: a review of the approaches with focus on dielectrophoretic and magnetophoretic methods , 2016, Malaria Journal.
[18] Juliana K. Wambua,et al. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. , 2016, The New England journal of medicine.
[19] Frederick R. Haselton,et al. Mobile phone imaging and cloud-based analysis for standardized malaria detection and reporting , 2016, Scientific Reports.
[20] C. Rogier,et al. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. , 2016, The New England journal of medicine.
[21] M. Chavchich,et al. The Spiroindolone KAE609 Does Not Induce Dormant Ring Stages in Plasmodium falciparum Parasites , 2016, Antimicrobial Agents and Chemotherapy.
[22] A. Dicko,et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. , 2016, The Lancet. Infectious diseases.
[23] R. Garfein,et al. Digital health for the End TB Strategy: developing priority products and making them work , 2016, European Respiratory Journal.
[24] D. Kwiatkowski,et al. Elusive Plasmodium Species Complete the Human Malaria Genome Set , 2016, bioRxiv.
[25] J. McCarthy,et al. Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects , 2016, British journal of clinical pharmacology.
[26] K. Bourtzis,et al. More than one rabbit out of the hat: Radiation, transgenic and symbiont-based approaches for sustainable management of mosquito and tsetse fly populations. , 2016, Acta tropica.
[27] J. Hemingway,et al. Averting a malaria disaster: will insecticide resistance derail malaria control? , 2016, The Lancet.
[28] J. McCarthy,et al. Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development , 2016, Antimicrobial Agents and Chemotherapy.
[29] L. von Seidlein,et al. The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan , 2016, PLoS medicine.
[30] P. Gething,et al. Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. , 2016, The Lancet. Infectious diseases.
[31] Jane M. Carlton,et al. A Method for Amplicon Deep Sequencing of Drug Resistance Genes in Plasmodium falciparum Clinical Isolates from India , 2016, Journal of Clinical Microbiology.
[32] A. Tompkins,et al. A Regional Model for Malaria Vector Developmental Habitats Evaluated Using Explicit, Pond-Resolving Surface Hydrology Simulations , 2016, PloS one.
[33] T. Bousema,et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial , 2016, BMC Medicine.
[34] H. C. Chai,et al. Development of insulated isothermal PCR for rapid on-site malaria detection , 2016, Malaria Journal.
[35] J. McCarthy,et al. Novel molecular diagnostic tools for malaria elimination: a review of options from the point of view of high-throughput and applicability in resource limited settings , 2016, Malaria Journal.
[36] Andrea Pavesi,et al. Advances in microfluidics in combating infectious diseases , 2016, Biotechnology Advances.
[37] K. Miura. Progress and prospects for blood-stage malaria vaccines , 2016, Expert review of vaccines.
[38] O. Doumbo,et al. Gametocyte clearance dynamics following oral artesunate treatment of uncomplicated falciparum malaria in Malian children , 2016, Parasite.
[39] Joshua D. Hartzell,et al. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy , 2016, PLoS neglected tropical diseases.
[40] J. Cox,et al. Plasmodium knowlesi transmission: integrating quantitative approaches from epidemiology and ecology to understand malaria as a zoonosis , 2016, Parasitology.
[41] O. Doumbo,et al. Implementation of the malaria candidate vaccine RTS,S/AS01 , 2016, The Lancet.
[42] Katya Galactionova,et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models , 2016, The Lancet.
[43] D. Fidock,et al. Luciferase-Based, High-Throughput Assay for Screening and Profiling Transmission-Blocking Compounds against Plasmodium falciparum Gametocytes , 2016, Antimicrobial Agents and Chemotherapy.
[44] Stuart L. Schreiber,et al. High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission , 2016, Cell host & microbe.
[45] A. Hill,et al. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology , 2016, Scientific Reports.
[46] C. Chitnis,et al. Development of vaccines for Plasmodium vivax malaria. , 2015, Vaccine.
[47] T. Horii,et al. Recent advances in recombinant protein-based malaria vaccines , 2015, Vaccine.
[48] D. Kaslow,et al. RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap. , 2015, Vaccine.
[49] R. Verity,et al. Vaccine approaches to malaria control and elimination: Insights from mathematical models. , 2015, Vaccine.
[50] Andrea Crisanti,et al. A CRISPR-Cas9 Gene Drive System Targeting Female Reproduction in the Malaria Mosquito vector Anopheles gambiae , 2015, Nature Biotechnology.
[51] W. Focke,et al. Acceptability and effectiveness of a monofilament, polyethylene insecticide-treated wall lining for malaria control after six months in dwellings in Vhembe District, Limpopo Province, South Africa , 2015, Malaria Journal.
[52] S. Li,et al. Editorial: Why Vaccines to HIV, HCV, and Malaria Have So Far Failed—Challenges to Developing Vaccines Against Immunoregulating Pathogens , 2015, Front. Microbiol..
[53] Pedro Alonso,et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines , 2015, Vaccine.
[54] Ethan Bier,et al. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi , 2015, Proceedings of the National Academy of Sciences.
[55] Christopher V. Plowe. Vaccine-Resistant Malaria. , 2015, The New England journal of medicine.
[56] Trevor Bedford,et al. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. , 2015, The New England journal of medicine.
[57] J. Logedi,et al. Feasibility of an innovative electronic mobile system to assist health workers to collect accurate, complete and timely data in a malaria control programme in a remote setting in Kenya , 2015, Malaria Journal.
[58] Brian J. Johnson,et al. The Siren's Song: Exploitation of Female Flight Tones to Passively Capture Male Aedes aegypti (Diptera: Culicidae) , 2015, Journal of Medical Entomology.
[59] J. Rubio,et al. Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping , 2015, The Journal of infectious diseases.
[60] Ludovic P Ahoua Alou,et al. Efficacy of Olyset® Duo, a permethrin and pyriproxyfen mixture net against wild pyrethroid-resistant Anopheles gambiae s.s. from Côte d’Ivoire: an experimental hut trial , 2015, Parasite.
[61] Ludovic P Ahoua Alou,et al. Insecticidal and sterilizing effect of Olyset Duo®, a permethrin and pyriproxyfen mixture net against pyrethroid-susceptible and -resistant strains of Anopheles gambiae s.s.: a release-recapture assay in experimental huts , 2015, Parasite.
[62] S. Agnandji,et al. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials. , 2015, Future microbiology.
[63] J. Beier,et al. Formulation of attractive toxic sugar bait (ATSB) with safe EPA-exempt substance significantly diminishes the Anopheles sergentii population in a desert oasis. , 2015, Acta tropica.
[64] Yuming Guo,et al. The effect of air pollution on human physiological function in China: a longitudinal study , 2015, The Lancet.
[65] D K Das,et al. Computational microscopic imaging for malaria parasite detection: a systematic review , 2015, Journal of microscopy.
[66] Q. Bassat,et al. Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model , 2015, PLoS medicine.
[67] R. Price,et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report , 2015, Malaria Journal.
[68] David Malone,et al. Disruptive technology for vector control: the Innovative Vector Control Consortium and the US Military join forces to explore transformative insecticide application technology for mosquito control programmes , 2015, Malaria Journal.
[69] U. Dalrymple,et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015 , 2015, Nature.
[70] D. Ndiaye,et al. Malaria Diagnosis across the International Centers of Excellence for Malaria Research: Platforms, Performance, and Standardization , 2015, The American journal of tropical medicine and hygiene.
[71] H. Ranson,et al. Electrostatic coating enhances bioavailability of insecticides and breaks pyrethroid resistance in mosquitoes , 2015, Proceedings of the National Academy of Sciences.
[72] Gonzalo Colmenarejo,et al. A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery , 2015, PloS one.
[73] P. Michel,et al. A systematic, realist review of zooprophylaxis for malaria control , 2015, Malaria Journal.
[74] S. Hoffman,et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates , 2015, Malaria Journal.
[75] L. Rénia,et al. Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax , 2015, Front. Immunol..
[76] U. d’Alessandro,et al. Transdermal Diagnosis of Malaria Using Vapor Nanobubbles , 2015, Emerging infectious diseases.
[77] F. Tripet,et al. Targeting male mosquito mating behaviour for malaria control , 2015, Parasites & Vectors.
[78] A. Wilke,et al. Paratransgenesis: a promising new strategy for mosquito vector control , 2015, Parasites & Vectors.
[79] Hannah C. Slater,et al. Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda , 2015, Malaria Journal.
[80] I. Kleinschmidt,et al. The evidence for improving housing to reduce malaria: a systematic review and meta-analysis , 2015, Malaria Journal.
[81] Farah El Mazouni,et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria , 2015, Science Translational Medicine.
[82] T. Bousema,et al. A combination of new screening assays for prioritization of transmission-blocking antimalarials reveals distinct dynamics of marketed and experimental drugs. , 2015, The Journal of antimicrobial chemotherapy.
[83] P. Rosenthal,et al. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso , 2015, Antimicrobial Agents and Chemotherapy.
[84] Peter G. Kremsner,et al. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. , 2015 .
[85] O. Vandal,et al. Killing the hypnozoite – drug discovery approaches to prevent relapse in Plasmodium vivax , 2015, Pathogens and global health.
[86] S. Hoffman,et al. Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum , 2015, Malaria Journal.
[87] A. Vaughan,et al. Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. , 2015, Cell host & microbe.
[88] Sujin Lee,et al. Recent Advances of Vaccine Adjuvants for Infectious Diseases , 2015, Immune network.
[89] Evelyn Siu,et al. Modeling malaria in humanized mice: opportunities and challenges , 2015, Annals of the New York Academy of Sciences.
[90] Stephen C. Trowell,et al. Analysis of Breath Specimens for Biomarkers of Plasmodium falciparum Infection , 2015, The Journal of infectious diseases.
[91] D. Leboulleux,et al. Design of a Phase III cluster randomized trial to assess the efficacy and safety of a malaria transmission blocking vaccine. , 2015, Vaccine.
[92] R. Sinden,et al. Imaging-Based High-Throughput Screening Assay To Identify New Molecules with Transmission-Blocking Potential against Plasmodium falciparum Female Gamete Formation , 2015, Antimicrobial Agents and Chemotherapy.
[93] S. Hoffman,et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres , 2015, Malaria Journal.
[94] H. Liao,et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. , 2015, The Journal of infectious diseases.
[95] Fatimah Ibrahim,et al. The Application of Biomedical Engineering Techniques to the Diagnosis and Management of Tropical Diseases: A Review , 2015, Sensors.
[96] P. Garner,et al. Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission , 2015, The Cochrane database of systematic reviews.
[97] D. Pillai,et al. Evaluation of non-instrumented nucleic acid amplification by loop-mediated isothermal amplification (NINA-LAMP) for the diagnosis of malaria in Northwest Ethiopia , 2015, Malaria Journal.
[98] Abdullah S. Ali,et al. Loop-mediated isothermal amplification (LAMP) for point-of-care detection of asymptomatic low-density malaria parasite carriers in Zanzibar , 2015, Malaria Journal.
[99] Teun Bousema,et al. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. , 2014, The Journal of infectious diseases.
[100] I. Elyazar,et al. Impact of a spatial repellent on malaria incidence in two villages in Sumba, Indonesia. , 2014, The American journal of tropical medicine and hygiene.
[101] Y. Takwoingi,et al. Rapid diagnostic tests for diagnosing uncomplicated non‐falciparum or Plasmodium vivax malaria in endemic countries , 2014, The Cochrane database of systematic reviews.
[102] A. Dao,et al. Signatures of aestivation and migration in Sahelian malaria mosquito populations , 2014, Nature.
[103] B. Genton,et al. Comparison of detection methods to estimate asexual Plasmodium falciparum parasite prevalence and gametocyte carriage in a community survey in Tanzania , 2014, Malaria Journal.
[104] S. Hay,et al. Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission , 2014, eLife.
[105] B. Lige,et al. The performance evaluation of a urine malaria test (UMT) kit for the diagnosis of malaria in individuals with fever in south-east Nigeria: cross-sectional analytical study , 2014, Malaria Journal.
[106] S. Meshnick,et al. Field evaluation of a real-time fluorescence loop-mediated isothermal amplification assay, RealAmp, for the diagnosis of malaria in Thailand and India. , 2014, The Journal of infectious diseases.
[107] D. Kaslow,et al. Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward. , 2014, Vaccine.
[108] G. Killeen,et al. Characterizing, controlling and eliminating residual malaria transmission , 2014, Malaria Journal.
[109] W. Focke,et al. Development of an insecticide impregnated polymer wall lining for malaria vector control , 2014, Malaria Journal.
[110] G. A. Ngwa,et al. On a Reproductive Stage-Structured Model for the Population Dynamics of the Malaria Vector , 2014, Bulletin of Mathematical Biology.
[111] J. Beier,et al. Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination , 2014, Parasitology Research.
[112] N. Chandrasekaran,et al. Study on antimicrobial potential of neem oil nanoemulsion against Pseudomonas aeruginosa infection in Labeo rohita , 2014, Biotechnology and applied biochemistry.
[113] Baldur P Magnusson,et al. A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Imidazolopiperazine KAF156 To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers , 2014, Antimicrobial Agents and Chemotherapy.
[114] Baldur P Magnusson,et al. A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers , 2014, Antimicrobial Agents and Chemotherapy.
[115] Dean P. Jones,et al. Metabolomics in the fight against malaria , 2014, Memorias do Instituto Oswaldo Cruz.
[116] Kanika Thakur,et al. Docetaxel loaded chitosan nanoparticles: formulation, characterization and cytotoxicity studies. , 2014, International journal of biological macromolecules.
[117] Peter Chiodini,et al. Plasmodium falciparum parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting , 2014, Malaria Journal.
[118] George M Church,et al. Concerning RNA-guided gene drives for the alteration of wild populations , 2014, bioRxiv.
[119] Austin Burt,et al. Heritable strategies for controlling insect vectors of disease , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.
[120] C. Ockenhouse,et al. Controlled human malaria infection. , 2014, The Journal of infectious diseases.
[121] S. Moore,et al. A household randomized, controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination with long-lasting insecticidal nets on the incidence of Plasmodium falciparum and Plasmodium vivax malaria in Western Yunnan Province, China , 2014, Malaria Journal.
[122] A. Mbonye,et al. A lab-on-chip for malaria diagnosis and surveillance , 2014, Malaria Journal.
[123] N. Valecha,et al. Comparison of three PCR-based assays for the non-invasive diagnosis of malaria: detection of Plasmodium parasites in blood and saliva , 2014, European Journal of Clinical Microbiology & Infectious Diseases.
[124] R. Chhem,et al. Current status and future challenges for controlling malaria with the sterile insect technique: technical and social perspectives. , 2014, Acta tropica.
[125] M. Harry,et al. Biting by Anopheles funestus in broad daylight after use of long-lasting insecticidal nets: a new challenge to malaria elimination , 2014, Malaria Journal.
[126] Malaya K. Sahoo,et al. Multiplex Nucleic Acid Amplification Test for Diagnosis of Dengue Fever, Malaria, and Leptospirosis , 2014, Journal of Clinical Microbiology.
[127] S. Krudsood,et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study , 2014, The Lancet.
[128] G. Killeen,et al. Potential causes and consequences of behavioural resilience and resistance in malaria vector populations: a mathematical modelling analysis , 2014, Malaria Journal.
[129] P. Rosenthal,et al. Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda , 2014, Malaria Journal.
[130] Rakesh K. Sharma,et al. Anti HIV nanoemulsion formulation: optimization and in vitro-in vivo evaluation. , 2014, International journal of pharmaceutics.
[131] M. Rowland,et al. Mosquito Nets Treated with a Mixture of Chlorfenapyr and Alphacypermethrin Control Pyrethroid Resistant Anopheles gambiae and Culex quinquefasciatus Mosquitoes in West Africa , 2014, PloS one.
[132] O. Sarr,et al. Analysis of pfhrp2 genetic diversity in Senegal and implications for use of rapid diagnostic tests , 2014, Malaria Journal.
[133] O. Billker,et al. Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites , 2013, Infection and Immunity.
[134] B. Genton,et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.
[135] E. Winzeler,et al. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. , 2013, The Journal of infectious diseases.
[136] M. Rossignol,et al. Efficacy of Olyset® Plus, a New Long-Lasting Insecticidal Net Incorporating Permethrin and Piperonil-Butoxide against Multi-Resistant Malaria Vectors , 2013, PloS one.
[137] C. Rogier,et al. The changes in mosquito vector behaviour and the emerging resistance to insecticides will challenge the decline of malaria. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[138] M. P. Griffin,et al. A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults , 2013, Antimicrobial Agents and Chemotherapy.
[139] A. M. de Oliveira,et al. Multiple genetic origins of histidine-rich protein 2 gene deletion in Plasmodium falciparum parasites from Peru , 2013, Scientific Reports.
[140] Peter Siba,et al. Strategies for Detection of Plasmodium species Gametocytes , 2013, PloS one.
[141] Steven W Lindsay,et al. Mosquito larval source management for controlling malaria. , 2013, The Cochrane database of systematic reviews.
[142] John M. Marshall,et al. Quantifying the mosquito’s sweet tooth: modelling the effectiveness of attractive toxic sugar baits (ATSB) for malaria vector control , 2013, Malaria Journal.
[143] Anne E Carpenter,et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. , 2013, Cell host & microbe.
[144] N. Chitnis,et al. Effects of changing mosquito host searching behaviour on the cost effectiveness of a mass distribution of long-lasting, insecticidal nets: a modelling study , 2013, Malaria Journal.
[145] A. Jin,et al. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. , 2013, Vaccine.
[146] J. Burrows,et al. Designing the next generation of medicines for malaria control and eradication , 2013, Malaria Journal.
[147] Q. Bassat,et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination , 2013, Malaria Journal.
[148] C. Mbogo,et al. The role of Anopheles arabiensis and Anopheles coustani in indoor and outdoor malaria transmission in Taveta District, Kenya , 2013, Parasites & Vectors.
[149] G. Killeen,et al. Entomological surveillance of behavioural resilience and resistance in residual malaria vector populations , 2013, Malaria Journal.
[150] Martin Walker,et al. Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection , 2013, eLife.
[151] John M. Marshall,et al. THE IMPORTANCE OF MOSQUITO BEHAVIOURAL ADAPTATIONS TO MALARIA CONTROL IN AFRICA , 2013, Evolution; international journal of organic evolution.
[152] N. Hung,et al. Cost-Effectiveness of Long-Lasting Insecticide-Treated Hammocks in Preventing Malaria in South-Central Vietnam , 2013, PloS one.
[153] N. Beebe,et al. Successful malaria elimination strategies require interventions that target changing vector behaviours , 2013, Malaria Journal.
[154] J. McCarthy,et al. Experimentally induced blood stage malaria infection as a tool for clinical research. , 2012, Trends in parasitology.
[155] Søren K Rasmussen,et al. Recombinant antibody mixtures: production strategies and cost considerations. , 2012, Archives of biochemistry and biophysics.
[156] O. Doumbo,et al. Mosquito Feeding Assays to Determine the Infectiousness of Naturally Infected Plasmodium falciparum Gametocyte Carriers , 2012, PloS one.
[157] R. Price,et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature , 2012, Malaria Journal.
[158] R. Sauerwein,et al. A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. , 2012, Vaccine.
[159] A. Ghosh,et al. Fighting malaria with engineered symbiotic bacteria from vector mosquitoes , 2012, Proceedings of the National Academy of Sciences.
[160] D. Meyrowitsch,et al. Change in composition of the Anopheles gambiae complex and its possible implications for the transmission of malaria and lymphatic filariasis in north-eastern Tanzania , 2012, Malaria Journal.
[161] A. Vaughan,et al. Development of humanized mouse models to study human malaria parasite infection. , 2012, Future microbiology.
[162] J. Lelièvre,et al. Activity of Clinically Relevant Antimalarial Drugs on Plasmodium falciparum Mature Gametocytes in an ATP Bioluminescence “Transmission Blocking” Assay , 2012, Malaria Journal.
[163] D. Leroy,et al. Comparison and Optimization of Different Methods for the In Vitro Production of Plasmodium falciparum Gametocytes , 2012, Journal of parasitology research.
[164] Arantxa Roca-Feltrer,et al. Estimating the potential public health impact of seasonal malaria chemoprevention in African children , 2012, Nature Communications.
[165] A. James,et al. Why RIDL is not SIT. , 2011, Trends in parasitology.
[166] Adalgisa Caccone,et al. Outdoor host seeking behaviour of Anopheles gambiae mosquitoes following initiation of malaria vector control on Bioko Island, Equatorial Guinea , 2011, Malaria Journal.
[167] Tanya L Russell,et al. Increased proportions of outdoor feeding among residual malaria vector populations following increased use of insecticide-treated nets in rural Tanzania , 2011, Malaria Journal.
[168] Andrea Crisanti,et al. A synthetic homing endonuclease-based gene drive system in the human malaria mosquito , 2011, Nature.
[169] M. Chen-Mok,et al. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. , 2011, The American journal of tropical medicine and hygiene.
[170] Yongyuth Yuthavong,et al. A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.
[171] Frank H. Collins,et al. A Research Agenda for Malaria Eradication: Vector Control , 2011, PLoS medicine.
[172] Prashant Yadav,et al. A Research Agenda for Malaria Eradication: Vaccines , 2019 .
[173] David Schellenberg,et al. A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics , 2011, PLoS medicine.
[174] M. Rowland,et al. An experimental hut evaluation of PermaNet(®) 3.0, a deltamethrin-piperonyl butoxide combination net, against pyrethroid-resistant Anopheles gambiae and Culex quinquefasciatus mosquitoes in southern Benin. , 2010, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[175] Kamolrat Silamut,et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial , 2010, The Lancet.
[176] M. Pascual,et al. Transmission Intensity and Drug Resistance in Malaria Population Dynamics: Implications for Climate Change , 2010, PloS one.
[177] Thomas Smith,et al. Comparing the Effectiveness of Malaria Vector-Control Interventions Through a Mathematical Model , 2010, The American journal of tropical medicine and hygiene.
[178] J. Baird,et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. , 2010, Trends in parasitology.
[179] M. Perkins,et al. A Large Proportion of P. falciparum Isolates in the Amazon Region of Peru Lack pfhrp2 and pfhrp3: Implications for Malaria Rapid Diagnostic Tests , 2010, PloS one.
[180] Olivier Pigeon,et al. Evaluation of PermaNet 3.0 a deltamethrin-PBO combination net against Anopheles gambiae and pyrethroid resistant Culex quinquefasciatus mosquitoes: an experimental hut trial in Tanzania , 2010, Malaria Journal.
[181] Brian Kelley,et al. Industrialization of mAb production technology: The bioprocessing industry at a crossroads , 2009, mAbs.
[182] C. Plowe,et al. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’ , 2009, Parasite immunology.
[183] J. Carlton,et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. , 2007, The Journal of infectious diseases.
[184] M. Gatton,et al. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. , 2007, The Journal of infectious diseases.
[185] J. Verhave,et al. Age-dependent distribution of Plasmodium falciparum gametocytes quantified by Pfs25 real-time QT-NASBA in a cross-sectional study in Burkina Faso. , 2007, The American journal of tropical medicine and hygiene.
[186] Arjen Dondorp,et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial , 2005, The Lancet.
[187] W. Watkins,et al. Intensity of malaria transmission and the evolution of drug resistance. , 2005, Acta tropica.
[188] D. Kaslow,et al. Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability of Plasmodium vivax To Infect Mosquitoes , 2000, Infection and Immunity.
[189] Joe D. Cohen,et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.
[190] B. Maegraith. Liverpool School of Tropical Medicine , 1907, Nature.
[191] B. Birren,et al. Genetic Diversity and Protective Efficacy of the RTS , S / AS 01 Malaria Vaccine , 2015 .
[192] Gao Qi,et al. Global technical strategy for malaria 2016–2030 , 2015 .
[193] T. Bousema,et al. Quantification of female and male Plasmodium falciparum gametocytes by reverse transcriptase quantitative PCR. , 2015, Molecular and biochemical parasitology.
[194] Andrea Crisanti,et al. A CRISPR-Cas 9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae , 2015 .
[195] M. Coosemans,et al. Residual transmission of malaria : an old issue for new approaches , 2013 .
[196] T. Bousema,et al. A protocol for membrane feeding assays to determine the infectiousness of P. falciparum naturally infected individuals to Anopheles gambiae , 2013 .
[197] Weltgesundheitsorganisation. World malaria report , 2005 .
[198] J. A. Downes. The Swarming and Mating Flight of Diptera , 1969 .